NPHLA Daily — November 13, 2026

Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.

Top development today

What changed today in Metabolic: 13 trial updates, 2 new studies

NPHLA tracked 15 new official records on this desk today: 2 new studies, 13 trial updates. First: New research in Lancet (London, England): “Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity…”.

Metabolic signal

New trial registered: AMBITION 3 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body…)

Phase 3, Novo Nordisk A/S. Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.

Regulatory signal

What changed today in Regulatory: 1 safety alert, 1 recall record

NPHLA tracked 2 new official records on this desk today: 1 safety alert, 1 recall record. First: Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen

Aesthetics & Longevity signal

What changed today in Aesthetics & Longevity: 2 new studies, 1 trial update

NPHLA tracked 3 new official records on this desk today: 2 new studies, 1 trial update. First: New research in In vitro cellular & developmental biology. Animal: “Hypoxia preconditioning improves the anti-senescence potency of umbilical cord mesenchymal stem cell-derived…

AI & Technology signal

What changed today in AI & Technology: 1 new study

NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Advances in health information science and practice: “AI Governance in Health Information Practice: A Practical Framework for HIPAA-Compliant AI Adoption”.

One thing worth watching

Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…

November 26, 2026 — verified from the Federal Register comments_close_on.

5 things to know

Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.